SCHEMBL7039876

SCHEMBL7039876

CCOC(=O)c1sc(Oc2ccc(OCc3ccccc3)cc2)c2c1CCc1cnn(C)c1-2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 5/20 0.53
CDK8 P49336 5/20 0.53
CDK19 Q9BWU1 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
ADORA2A P29274 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
CDK4 P11802 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCND3 P30281 1/20 0.38
CCNA1 P78396 1/20 0.38
CDK6 Q00534 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7242256 0.91 CCNC (0.58) CCNCCDK8CDK19SMN1; SMN2ADORA2A
SCHEMBL7039481 0.89 CCNC (0.65) CCNCCDK8CDK19
SCHEMBL7249230 0.88 CCNC (0.55) CCNCCDK8CDK19SMN1; SMN2DRD2
SCHEMBL7038611 0.87 CCNC (0.49) CCNCCDK8CDK19
SCHEMBL7249746 0.86 CCNC (0.56) CCNCCDK8CDK19SMN1; SMN2DRD2
SCHEMBL7244945 0.86 CCNC (0.54) CCNCCDK8CDK19SMN1; SMN2POLB
SCHEMBL7248569 0.86 CCNC (0.56) CCNCCDK8CDK19SMN1; SMN2DRD2
SCHEMBL7243215 0.84 CCNC (0.53) CCNCCDK8CDK19SMN1; SMN2DRD2
SCHEMBL7242502 0.84 CCNC (0.52) CCNCCDK8CDK19SMN1; SMN2DRD2
SCHEMBL15104779 0.84 CCNC (0.52) CCNCCDK8CDK19SMN1; SMN2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030185878-A1 Process for producing phospholipid-containing drug TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1293197-A1 PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030185878-A1 Process for producing phospholipid-containing drug PHOSPHO1, PLTP, PTDSS2 CCNC 3385/4885CDK8 2673/4885CDK19 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.